Robert A. Dean

9.3k total citations · 1 hit paper
91 papers, 5.9k citations indexed

About

Robert A. Dean is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Robert A. Dean has authored 91 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Physiology, 26 papers in Psychiatry and Mental health and 24 papers in Molecular Biology. Recurrent topics in Robert A. Dean's work include Alzheimer's disease research and treatments (49 papers), Dementia and Cognitive Impairment Research (25 papers) and Computational Drug Discovery Methods (14 papers). Robert A. Dean is often cited by papers focused on Alzheimer's disease research and treatments (49 papers), Dementia and Cognitive Impairment Research (25 papers) and Computational Drug Discovery Methods (14 papers). Robert A. Dean collaborates with scholars based in United States, United Kingdom and Belgium. Robert A. Dean's co-authors include Eric Siemers, Kaj Blennow, Leslie M. Shaw, John Q. Trojanowski, William Z. Potter, Paul Aisen, Piotr Lewczuk, Holly Soares, Hugo Vanderstichele and Virginia M.‐Y. Lee and has published in prestigious journals such as Journal of Biological Chemistry, Blood and PLoS ONE.

In The Last Decade

Robert A. Dean

87 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

2009 1.6k citations Leslie M. Shaw, Hugo Vanderstichele et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert A. Dean United States	30	3.5k	2.0k	1.4k	1.2k	764	91	5.9k
Hans Basun Sweden	50	4.2k 1.2×	2.1k 1.0×	1.6k 1.2×	869 0.7×	408 0.5×	133	7.4k
Shobha Dhadda United States	25	2.6k 0.7×	1.6k 0.8×	893 0.6×	1.1k 0.9×	505 0.7×	70	5.4k
Lynn D. Kramer United States	21	2.4k 0.7×	2.1k 1.0×	927 0.7×	765 0.6×	447 0.6×	64	5.0k
Kate Zhong United States	24	2.6k 0.7×	1.4k 0.7×	1.3k 0.9×	1.4k 1.2×	851 1.1×	35	5.4k
Kwasi G. Mawuenyega United States	24	3.9k 1.1×	1.6k 0.8×	1.7k 1.2×	672 0.6×	413 0.5×	34	5.9k
Andrea Vergallo France	29	2.3k 0.7×	1.2k 0.6×	1.3k 0.9×	1.0k 0.9×	484 0.6×	79	4.8k
Christiane Reitz United States	40	3.7k 1.1×	2.4k 1.2×	1.9k 1.4×	643 0.5×	361 0.5×	113	8.1k
Zaven S. Khachaturian United States	25	3.2k 0.9×	1.5k 0.7×	1.8k 1.3×	1.3k 1.1×	536 0.7×	81	6.2k
Bruno P. Imbimbo Italy	54	4.5k 1.3×	1.4k 0.7×	2.0k 1.5×	2.1k 1.7×	959 1.3×	276	10.1k
Larisa Reyderman United States	24	2.2k 0.6×	1.2k 0.6×	1.2k 0.9×	817 0.7×	444 0.6×	107	5.2k

Countries citing papers authored by Robert A. Dean

Since Specialization

Citations

This map shows the geographic impact of Robert A. Dean's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Dean with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Dean more than expected).

Fields of papers citing papers by Robert A. Dean

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Dean. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Dean. The network helps show where Robert A. Dean may publish in the future.

Co-authorship network of co-authors of Robert A. Dean

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Dean. A scholar is included among the top collaborators of Robert A. Dean based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Dean. Robert A. Dean is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cline, Erika N., Karen Sundell, Elizabeth A. Johnson, et al.. (2025). Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease. The Journal of Prevention of Alzheimer s Disease. 12(4). 100082–100082. 2 indexed citations

Dean, Robert A., et al.. (2021). Hydrothermal carbonization of simulated food waste for recovery of fatty acids and nutrients. Bioresource Technology. 341. 125872–125872. 35 indexed citations

Shaw, Leslie M., Teresa Waligórska, Leona Fields, et al.. (2018). Derivation of cutoffs for the Elecsys^® amyloid β (1–42) assay in Alzheimer's disease. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 10(1). 698–705. 54 indexed citations

Mattsson, Niklas, María C. Carrillo, Robert A. Dean, et al.. (2015). Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 1(4). 412–419. 69 indexed citations

Figurski, Michal, Teresa Waligórska, Magdalena Korecka, et al.. (2015). P1‐119: Prospective quality‐control monitoring in the context of a clinical trial. Alzheimer s & Dementia. 11(7S_Part_8). 1 indexed citations

Dean, Robert A., Leslie M. Shaw, Teresa Waligórska, et al.. (2014). P4‐076: INCLUSION OF PATIENTS WITH ALZHEIMER'S DISEASE PATHOLOGY IN SOLANEZUMAB EXPEDITION 3 USING FLORBETAPIR PET IMAGING OR INNO‐BIA ALZBIO3 CSF Aβ1‐42. Alzheimer s & Dementia. 10(4S_Part_22). 7 indexed citations

Portelius, Erik, Robert A. Dean, Ulf Andréasson, et al.. (2014). β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage. Alzheimer s Research & Therapy. 6(5-8). 75–75. 29 indexed citations

Ma, Xiwen, Karen Sundell, Karla Alaka, et al.. (2014). P1‐366: USE OF QUANTILE REGRESSION TO CHARACTERIZE SOLANEZUMAB EFFECTS ACROSS PERCENTILES OF DISEASE PROGRESSION IN EXPEDITION ALZHEIMER'S DISEASE TRIALS. Alzheimer s & Dementia. 10(4S_Part_11). 2 indexed citations

Henriksen, Kim, Yaguo Wang, Mette G Sørensen, et al.. (2013). An Enzyme-Generated Fragment of Tau Measured in Serum Shows an Inverse Correlation to Cognitive Function. PLoS ONE. 8(5). e64990–e64990. 30 indexed citations

10.

Kielbasa, William, Tonya Quinlan, Ling Jin, et al.. (2012). Pharmacokinetics and Pharmacodynamics of Edivoxetine (LY2216684), a Norepinephrine Reuptake Inhibitor, in Pediatric Patients with Attention-Deficit/ Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. 22(4). 269–276. 13 indexed citations

11.

Shaw, Leslie M., Hugo Vanderstichele, Małgorzata Knapik-Czajka, et al.. (2011). Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathologica. 121(5). 597–609. 235 indexed citations

12.

Hale, John E., Valentina Gelfanova, Jinsam You, Michael D. Knierman, & Robert A. Dean. (2008). Proteomics of Cerebrospinal Fluid: Methods for Sample Processing. Methods in molecular biology. 53–66. 14 indexed citations

13.

Siemers, Eric, Robert A. Dean, Stuart Friedrich, et al.. (2007). Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-β After Inhibition of γ-Secretase. Clinical Neuropharmacology. 30(6). 317–325. 121 indexed citations

14.

Oe, Tomoyuki, Bradley L. Ackermann, Kōichi Inoue, et al.. (2006). Quantitative analysis of amyloid β peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry. 20(24). 3723–3735. 133 indexed citations

15.

Walsh, Brian W., David A. Cox, Andreas Sashegyi, et al.. (2001). Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. The American Journal of Cardiology. 88(7). 825–828. 60 indexed citations

16.

Kedishvili, Natalia Y., Trent L. Abraham, Monica R. Brzezinski, et al.. (1997). Purification and Cloning of a Broad Substrate Specificity Human Liver Carboxylesterase That Catalyzes the Hydrolysis of Cocaine and Heroin. Journal of Biological Chemistry. 272(23). 14769–14775. 183 indexed citations

17.

Dean, Robert A., et al.. (1996). Serum ethylene glycol by high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 685(2). 370–374. 12 indexed citations

18.

Dean, Robert A.. (1993). Safety in the Elementary Science Classroom.

19.

Dean, Robert A., et al.. (1991). Human liver cocaine esterases: ethanol‐mediated formation of ethylcocaine. The FASEB Journal. 5(12). 2735–2739. 185 indexed citations

20.

Dean, Robert A.. (1988). Parent Survey: The Metcalf Full-Day Kindergarten.. 24(3). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact